Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8500a Effect on Rosuvastatin PK in Healthy Subjects
NCT03699774Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of firuglipel in type 2 diabetes mellitus (T2DM), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum observed plasma drug concentration, Time of maximum observed concentration and 1 more. Started May 2015; status: completed.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03699774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699774.